Skip to content

Glaxo Gets Approval for Myeloma Treatment in EU

August 27, 2020

GlaxoSmithKline PLC said late Wednesday that the European Commission has given conditional marketing authorization to its anti-B-cell maturation antigen therapy belantamab mafodotin.

The British pharmaceuticals giant said belantamab mafodotin has been approved as a monotherapy for the treatment of multiple myeloma in adult patient, in whom the disease was unresponsive to previous treatment.

Earlier this month, the U.S. Food and Drug Administration approved the use of belantamab mafodotin as a monotherapy in the U.S. too.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: